MarketMoodz
Dianthus Rallies After CAPTIVATE Midstage Win; Part B Due by 2026
Dianthus Therapeutics reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 program in chronic inflammatory demyelinating polyneuropathy (CIDP), sending DNTH shares higher Friday. The interim Part A readout showed a 75% confirmed responder rate and a favorable safety profile, while a Part B durability readout covering up to 52 weeks in responders is expected by end-2026.
Key Takeaways
- Interim Part A (40 patients) showed a 75% confirmed responder rate, up from a prior >50% readout.
- Safety was reported as favorable: no serious infections, no drug-induced lupus, and no safety-related discontinuations.
- Part B will assess durability up to 52 weeks in responders, with a readout window slated for end-2026.
- DNTH shares rose roughly 7.6% intraday, trading near $82.24 at the time of the Benzinga report.
- Claseprubart (DNTH103) is the investigational C1s antibody in the CAPTIVATE program, competing with drugs like Sanofi’s riliprubart.
People Involved
- Myles MinterAnalyst
- William BlairResearch firm (provided analyst commentary)
Entities Involved
- Dianthus Therapeutics Inc. (DNTH)Biotech developing claseprubart (DNTH103) for CIDP
- SanofiCompetitor developing riliprubart for CIDP
- CAPTIVATEPhase 3 clinical program evaluating claseprubart in CIDP
MarketMoodz Analysis
For investors, the Part A figures are a meaningful near-term green light: a 75% confirmed responder rate in 40 patients and a clean safety snapshot reduce binary risk heading into Part B and any late-stage regulatory discussions. The midstage surprise explains the roughly 7.6% intraday jump to about $82.24, but small-cap biotech moves often overshoot; the market is essentially pricing in improved odds that claseprubart can offer a durable, commercially relevant CIDP therapy if Part B confirms longer-term benefit.
Context matters: CIDP is a small but high-value market where durable responses and safety define commercial differentiation. Dianthus’s C1s-targeting antibody sits in a competitive field that includes Sanofi’s riliprubart and past signals from trials such as MOBILIZE; investors will compare Part B durability data directly to those benchmarks. Historically, early-phase responder rates can compress as patient numbers rise and follow-up lengthens, so Part B’s up-to-52-week durability readout (targeted for end-2026) is the critical next catalyst.
What to watch next: verify Part B’s exact endpoints, enrollment pace and any protocol differences from Part A that could affect comparability; monitor cash runway and potential for dilution or partnership discussions; and track competitive readouts from Sanofi and others that will shape pricing and market share assumptions. Remember the caveats — the Benzinga report and analyst comments aren’t primary-source press releases — so investors should await company disclosures and SEC filings for confirmation.
Source: Original Article